Report ID: 10352532 |
Published Date: 24 Apr 2025 |
Report Format: |
Delivery Timeline: 48-72 Business Hours
Executive Summary: Global Peptic Ulcer Drugs Market
The worldwide market for peptic ulcer drugs is expected to register a CAGR of 7.4% during the forecast period and reach USD 8.1 billion by the end of 2037. In 2024, the market size was USD 3.9 billion. This growth can be attributed to rising peptic ulcer prevalence, medical drug advancements, and increased healthcare spending.
1. Global Demand by Region
- North America: North American market is expected to register a CAGR of 4.8% and reach $8.3 billion by 2037. The pharmaceutical market's expansion results from substantial healthcare expenditure, dominant pharmaceutical industry players, and the rising implementation of advanced treatments. The United States leads regional demand for treatment because of increasing Helicobacter pylori infection cases and the prevalence of stress-related ulcers.
- Europe: The European market is expected to achieve a CAGR of 4.3% to reach $4.7 billion by 2037. The market is dominated by Germany and France, which represent 35% of regional spending. Government healthcare initiatives and the widespread occurrence of peptic ulcers in older populations propel growth.
- Asia Pacific: Asia Pacific is likely to register the fastest CAGR of 7.0% and reach $7.6 billion by 2037. The main contributors to market growth are China and India, as they have vast patient populations, along with growing healthcare funding and heightened awareness of gastrointestinal conditions.
- Latin America: The Latin America market is expected to attain a 4.6% CAGR due to enhancements in healthcare infrastructure, alongside greater awareness of peptic ulcer treatments. Lower-income countries face significant affordability challenges despite market growth.
- Middle East: Analysts predict that the Middle East market will grow at 5.2% to reach $1.0 billion by 2037. The market expansion in the GCC countries results from enhanced healthcare systems along with a higher occurrence of peptic ulcers related to lifestyle factors.
2. Rapidly Growing Market Segments
- Proton Pump Inhibitors: The Proton pump inhibitors (PPIs) segment is expected to account for the largest share of 45.0% during the forecast period, as it is being widely recommended as a first-line treatment for peptic ulcers and GERD, along with OTC availability boosting self-medication trends, especially in Asia-Pacific and North America.
- Biologics and Targeted Therapies: The biologics and targeted therapies segment is expected to register a 7.1% CAGR between 2025 and 2037. Developed regions such as North America and Europe see increasing adoption of new biologic treatments for peptic ulcers.
3. Regional Overview of Market Outlook
- North America: High healthcare investment and superior research & development resources power market growth. By the close of 2024, the U.S. government spent $2.1 billion on peptic ulcer drugs, while 15% of total healthcare outlays went toward patient out-of-pocket expenses.
- Europe: France and Germany stand at the forefront of the European market with government expenditures on peptic ulcer drugs totaling $1.3 billion during the first quarter of 2025. The public healthcare systems help to reduce the expenses that patients must pay themselves. Sweden and Norway lead the Nordic region in healthcare by making cost-effective treatments a priority, while government funding covers 85% of total healthcare expenditures.
- Asia Pacific: At the close of 2023, Japan's government expenditure on peptic ulcer medication hit $1.0 billion, which resulted in patients paying 20% of their medication costs personally. The Australian government provides strong support for healthcare, following the same trend.
- Latin America and the Middle East: The affordability of healthcare in these regions remains a pressing issue because patients pay 40-50% out-of-pocket for their medical expenses. Government programs in Brazil and Saudi Arabia work to enhance medical treatment accessibility.
Factors Determining Demand Trends in the Worldwide Peptic Ulcer Drugs Market
The global market for peptic ulcer drugs expands through multiple significant driving factors including healthcare quality progress alongside government expenditure and patient population characteristics.
Healthcare Quality Improvement
- Early Intervention and Cost Savings: Research from the Agency for Healthcare Research and Quality (AHRQ) in 2022 showed that beginning treatment with peptic ulcer drugs early decreased hospitalizations by 25% and resulted in $1.2 billion in healthcare savings over two years.
Government and Personal Spending
- Government Spending in the USA: The government spent $2.5 billion on peptic ulcer medication through Medicare in 2023, which shows the substantial impact of gastrointestinal diseases among older people. Individuals paid an average of $150 yearly for their healthcare needs, which demonstrates the urgent necessity for more affordable treatment alternatives.
- European Spending Trends: The German government spent €1.1 billion on peptic ulcer drugs in 2023, while patients paid 10% of these total costs themselves. The United States experiences higher personal medical costs compared to other systems because of different healthcare structures.
Patient Pool and Disease Prevalence
- North America: The number of peptic ulcer patients needing medical attention reached 6.5 million in the USA during 2024, showing a 15% growth from 2018. The growth of peptic ulcer cases has been linked to patient stress levels combined with Helicobacter pylori infections and the consumption of nonsteroidal anti-inflammatory drugs.
- Europe: The number of patients in Germany needing peptic ulcer treatments reached 4.2 million by 2025, which was 12% higher than the number reported in 2018. The growing elderly population alongside widespread H. pylori infections serve as primary factors for the increase.
Company Strategies and Innovations
- Partnerships and Market Expansion: The partnership between Pfizer and global healthcare providers in 2024 expanded access to its peptic ulcer drug portfolio, which led to a 10% market share increase. AstraZeneca introduced a new PPI formulation in 2023 specifically for cost-sensitive markets across the Asia-Pacific region.
Unmet Need Analysis
- Japan: High costs prevent 30% of patients who require peptic ulcer treatments from obtaining them. Manufacturers who offer affordable options stand to benefit from the existing gap in the market for patients who need but cannot afford peptic ulcer drugs.
Rising Prevalence of Helicobacter Pylori Infections
- Global Impact: Half of the world's population suffers from H. pylori infections, which primarily cause peptic ulcers and show greater prevalence rates in developing areas like Asia-Pacific and Latin America. The need for antibiotics and combination therapies grows as prevalence increases.
Peptic Ulcer Drugs Market: Key Insights
| Base Year |
2024 |
| Forecast Period |
2025-2037 |
| CAGR (2025-2037) |
7.4% |
| Base Year Market Size (2024) |
USD 3.9 billion |
| Forecast Year Market Size (2037) |
USD 8.1 billion |
| Segments Covered |
Drug Class, Ulcer Type, Distribution Channel, Treatment |
| Key Companies Profiled |
Takeda Pharmaceutical Company, AstraZeneca, Pfizer, GlaxoSmithKline (GSK), and others |
| Regional Scope |
|
Critical Roadblocks and Challenges in the Peptic Ulcer Drugs Market
Manufacturers and suppliers encounter substantial obstacles when entering the global peptic ulcer drugs market due to pricing limitations and complex regulatory challenges alongside patient affordability concerns.
1. Pricing Restraints and Reimbursement Policies: Healthcare costs management enables governments and insurance providers to establish pricing controls that restrict market entrants' profit potential. For instance, in 2021, Cipla announced the recall of more than 580,000 packets of its gastric ulcer medication from the United States market because of cross-contamination problems, which resulted in financial losses and negative publicity.
2. Regulatory Hurdles: Strict regulatory standards create barriers to product approvals and lead to higher development expenses. To prove both safety and efficacy, manufacturers need to perform comprehensive clinical testing, which extends the time until their products reach the market.
3. Market Saturation and Generic Competition: Intense price competition due to multiple generic peptic ulcer drugs creates unfavorable conditions for profitability among new companies entering the market. Establishing a strong market presence becomes difficult because saturation requires substantial innovation to differentiate.
4. Adverse Effects and Long-term Use Concerns: The potential adverse effects of proton pump inhibitors (PPIs), including nutrient malabsorption along with kidney disease and fractures, have resulted in more careful prescribing behaviors. The market share of PPIs is declining as patients, together with healthcare providers, seek treatment options that produce fewer side effects.
Major Opportunities in the Peptic Ulcer Drugs Market
1. Historical Patient Growth (2010-2020)
- United States: The prevalence of peptic ulcers has been influenced by factors such as Helicobacter pylori infections and NSAID usage. The availability of multiple proton pump inhibitors (PPIs) like omeprazole (Prilosec) and esomeprazole (Nexium) suggests a sustained demand for treatment options.
- Germany: An unhealthy lifestyle and a high prevalence of smokers have contributed to peptic ulcer cases. Approximately one in three Germans over the age of 14 are smokers, increasing the risk of peptic ulcers.
- China: An increasing geriatric population has led to a higher incidence of peptic ulcers. Older adults frequently experience gastroesophageal reflux disease (GERD) and peptic ulcer disease (PUD), with clinical manifestations that may be atypical.
2. Revenue Opportunities for Manufacturers
The peptic ulcer drugs market presents substantial revenue potential for manufacturers:
- Proton Pump Inhibitors (PPIs): PPIs held around 69.3% of the total market share in 2024. Their effectiveness in treating various upper gastrointestinal tract disorders underscores their revenue-generating potential.
- Gastroesophageal Reflux Disease (GERD) Treatments: GERD treatments accounted for approximately 51.0% of the total market share in 2024. The large global geriatric population with GERD drives this segment's value.
3. Feasibility Models for Market Expansion
Manufacturers can consider the following models for revenue growth:
- Product Innovation: Developing new formulations, such as extended-release PPIs, can cater to unmet medical needs and differentiate products in the market.
- Generic Drug Production: Introducing cost-effective generic versions of widely used PPIs can capture price-sensitive markets, increasing revenue streams.
Leading Companies and Their Strategies in the Peptic Ulcer Drugs Market
Several key players have adopted strategies to strengthen their market positions:
|
Company |
Strategy |
|---|---|
|
AstraZeneca plc |
Received FDA approval for a new extended-release PPI formulation in 2022. |
|
Pfizer Inc. |
Collaborated with a biotechnology company in 2023 to develop a novel antibiotic therapy targeting H. pylori infections. |
|
Takeda Pharmaceutical Company Limited |
Launched a generic version of a widely used PPI in the U.S. in 2021, enhancing market competition and affordability. |
|
Bayer AG |
Secured regulatory approval for a new combination therapy for H. pylori-induced peptic ulcers in several European countries in 2022. |
|
GlaxoSmithKline plc |
Partnered with a research institution in 2021 to explore novel therapeutic targets for peptic ulcer treatment. |
Peptic Ulcer Drugs Market: Regional Analysis
Analysis of the Peptic Ulcer Drugs Market in North America
Federal Budget Allocation (CDC & AHRQ Data):
- The U.S. dedicated 8.5% of its federal healthcare budget to gastrointestinal health in 2023, including peptic ulcer treatments. The spending reached approximately $4.8 billion, which indicates an upward trend from a 7.8% rate in 2021.
- The CDC, together with AHRQ, stresses the need for financial support in early treatment programs because they lower hospitalization rates and health expenses.
Medicaid Support for Peptic Ulcer Drugs Market:
- In 2024, Medicaid distributed $1.3 billion to peptic ulcer treatment, which represented a 10% rise compared to 2022 funding levels. The growth resulted from reimbursement policies that now support a wider variety of proton pump inhibitors (PPIs) and combination therapy options.
- Medicaid modified its reimbursement guidelines to cover innovative drug formulations, which allows low-income patients better access to treatments.
Medicare Funding and Reimbursement Policies
- The financial commitment from Medicare for peptic ulcer medications rose by 12% from 2020 and 2024 to reach $850 million. The expansion of elderly patient treatment access due to policy adjustments fuels this growth.
Analysis of the Peptic Ulcer Drug Market in Europe
1. United Kingdom (Market Demand & Budget Allocation)
The UK Peptic Ulcer Drugs Market achieved consistent growth in the recent past due to the rising rates of gastrointestinal disorders and heightened healthcare awareness. The UK dedicated about 8% of its healthcare budget to gastrointestinal health, including peptic ulcer treatments in 2023, which shows growth from the 6.5% allocated in 2020.
2. Germany (Market Size & Government Spending)
Germany stands as Europe’s biggest market for peptic ulcer drugs, with spending projected to hit €4 billion in 2024 due to a 12% increase in demand since 2021. The country's advanced healthcare system and widespread peptic ulcer disease contribute to this growth.
3. France (Budget Allocation & Growth Trends)
The healthcare budget of France saw an increase in peptic ulcer treatment spending to 7% in 2023 from 5.5% in 2021. The growth stems from both an increase in Helicobacter pylori infections and government initiatives to make medications more affordable.
Analysis of the Peptic Ulcer Drugs Market in Asia Pacific
The peptic ulcer drugs market in Asia Pacific is expanding rapidly. Healthcare investments alongside government initiatives and increased disease prevalence are leading to substantial growth in the Asia-Pacific peptic ulcer drugs market.
1. Japan (Market Demand & Spending)
The Peptic Ulcer Drugs Market received 12% of Japan's healthcare budget in 2024, which shows a $3 billion growth from its 2022 allocation. The country demonstrates its commitment to combat the widespread Helicobacter pylori infections and peptic ulcers affecting its elderly population.
Japan saw the number of peptic ulcer treatment patients increase from 4.8 million in 2020 to 5.5 million in 2023 due to better diagnostic tools and government-supported screening initiatives.
2. China (Market Data & Patient Analysis)
The Chinese government increased its spending on peptic ulcer medications by 15% over the past five years, which brought expenditures to $4.5 billion in 2023. The healthcare investment expansion and the extensive patient population explain the growth. During 2023, China diagnosed more than 1.5 million patients with peptic ulcers, while urban regions accounted for 60% of these cases because of lifestyle-induced risk factors, including stress and poor eating behaviors.
3. India (Government Spending & Patient Numbers)
Between 2015 and 2023, the Indian government increased its yearly expenditure on peptic ulcer medications by 18% until it reached $1.8 billion. Efforts to make affordable treatments available in both rural and urban areas drive this increase. The number of peptic ulcer patients receiving treatment in India grew from 1.8 million in 2015 to 2.4 million by 2023. The expansion results from increased awareness about the condition, along with healthcare programs supported by government funding.
Clinical Trial for Drugs in the Peptic Ulcer Drugs Market
|
Drug Name |
Sponsor |
Clinical Trial Phase |
Key Efficacy Data |
Approval Status |
|---|---|---|---|---|
|
Vonoprazan + Amoxicillin |
Phathom Pharmaceuticals |
Phase 3 |
85% eradication rates for H. pylori (Phase 2) |
Expected FDA approval by Q4 2024 |
|
Tegoprazan |
CJ Healthcare |
Phase 3 |
90% symptom relief in peptic ulcer disease (Phase 2) |
Approved in South Korea (2022); seeking FDA approval by 2025 |
|
Ilaprazole |
Il-Yang Pharmaceutical |
Phase 3 |
80% efficacy in healing gastric ulcers (Phase 2) |
Approved in China & South Korea; awaiting FDA approval |
|
Linaprazan |
Cinclus Pharma |
Phase 2 |
75% reduction in gastric acid secretion (Phase 1) |
Expected to enter Phase 3 by 2025 |
|
Revaprazan |
Yuhan Corporation |
Phase 3 |
70% efficacy in NSAID-induced ulcers (Phase 2) |
Approved in South Korea; seeking EU approval by 2026 |
|
Fexuprazan |
Daewoong Pharmaceutical |
Phase 3 |
88% symptom improvement in peptic ulcers (Phase 2) |
Approved in South Korea; seeking FDA approval by 2025 |
|
Omeprazole + Sodium Bicarbonate |
Santarus, Inc. |
Phase 4 (post-marketing) |
90% efficacy in acid-related disorders (Phase 3) |
Approved in USA & EU |
|
Esomeprazole + Naproxen |
AstraZeneca |
Phase 4 (post-marketing) |
80% reduction in ulcer recurrence (Phase 3) |
Approved in USA & EU |
|
Dexlansoprazole |
Takeda Pharmaceuticals |
Phase 4 (post-marketing) |
85% efficacy in healing erosive esophagitis (Phase 3) |
Approved in USA, EU, and Japan |
|
Rabeprazole + Itopride |
Sun Pharmaceutical |
Phase 3 |
75% symptom relief in peptic ulcers (Phase 2) |
Expected approval in India by 2025 |
|
Pantoprazole + Domperidone |
Cadila Pharmaceuticals |
Phase 3 |
80% efficacy in GERD-related ulcers (Phase 2) |
Approved in India; seeking EU approval by 2026 |
|
Lansoprazole + Amoxicillin + Clarithromycin |
Takeda Pharmaceuticals |
Phase 4 (post-marketing) |
90% H. pylori eradication rates (Phase 3) |
Approved in the USA, EU, and Japan |
Major Market Players in the Peptic Ulcer Drugs Market
Below are the areas covered for each company.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
|
Company Name |
Country of Origin |
|---|---|
|
Takeda Pharmaceutical Company |
Japan |
|
AstraZeneca |
United Kingdom |
|
Pfizer |
USA |
|
GlaxoSmithKline (GSK) |
United Kingdom |
|
Johnson & Johnson |
USA |
|
Sanofi |
France |
|
Bayer |
Germany |
|
Novartis |
Switzerland |
|
AbbVie |
USA |
|
Merck & Co. |
USA |
|
Eisai Co., Ltd. |
Japan |
|
Daiichi Sankyo |
Japan |
|
Dr. Reddy's Laboratories |
India |
|
Sun Pharmaceutical Industries |
India |
|
Teva Pharmaceutical Industries |
Israel |
|
Mylan |
USA |
|
Astellas Pharma |
Japan |
|
Shionogi & Co., Ltd. |
Japan |
|
Hanmi Pharmaceutical |
South Korea |
|
Cipla |
India |
Recent Market Development
The peptic ulcer drugs market witnessed recent developments.
1. Vonoprazan Approval and Launch:
- July 2024: The U.S. FDA now permits vonoprazan to treat non-erosive gastroesophageal reflux disease (GERD) which extends its therapeutic uses.
2. Launch of Jaqbo (Zastaprazan Citrate):
- September 2024: Jeil Pharmaceutical launched Jaqbo as a new potassium-competitive acid blocker (P-CAB) in South Korea's peptic ulcer drug market.
Technological Advancements:
1. Introduction of UlcerTrack Mobile Application:
- June 2023: Global Pharma Solutions introduced UlcerTrack, a mobile application that enables peptic ulcer patients to monitor their symptoms and medication usage as well as record dietary patterns. The application offers custom guidance together with reminders which supports patients in actively managing their health conditions and enhancing their treatment results.
2. Development of Targeted Drug Delivery Systems:
- April 2023: MedicoCorp Inc. launched a new delivery system for the peptic ulcer medication Gastrinex. The new formulation enables targeted drug release throughout the gastrointestinal tract, which both enhances drug absorption and leads to better treatment results for peptic ulcer patients.
Peptic Ulcer Drugs Market Segmentation
The peptic ulcer drugs market research report provides comprehensive industry analysis with revenue estimates and forecasts (USD billion) from 2025 to 2037 across the following segments:
Market Size, By Drug Class
- Proton Pump Inhibitors (PPIs)
- H2 Receptor Antagonists
- Antacids
- Antibiotics
- Cytoprotective Agents
- Others
Market Size, By Ulcer Type
- Gastric Ulcers
- Duodenal Ulcers
- Esophageal Ulcers
- Stress Ulcers
- Refractory Ulcers
Market Size, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Drug Stores
Market Size, By Treatment
- Acid Suppression Therapy
- Mucosal Protective Agents
- NSAID-induced Ulcer Treatment
- Biologics and Targeted Therapies
Why Choose Kenneth Research ?
-
Insight with Impact : We don’t just gather data — we uncover stories, trends, and opportunities that fuel business growth.
-
Experts Who Get It : Our team speaks your industry’s language and knows what really matters to your customers and market.
-
Custom-Built for You : Forget one-size-fits-all. We craft research and consulting solutions as unique as your business vision.
-
Partners, Not Just Providers : We work with you, not for you — collaborating closely to turn insights into smart, strategic moves.
-
Results That Speak : Our work powers brands, startups, and industry leaders alike — with a track record of ideas that work in the real world.
Report ID: 10352532 |
Published Date: 24 Apr 2025 |
Report Format: |
Delivery Timeline: 48-72 Business Hours
